{"id":568126,"date":"2025-11-11T16:13:11","date_gmt":"2025-11-11T16:13:11","guid":{"rendered":"https:\/\/www.europesays.com\/de\/568126\/"},"modified":"2025-11-11T16:13:11","modified_gmt":"2025-11-11T16:13:11","slug":"ms-forschung-kaum-ein-patient-landet-noch-im-rollstuhl-leben-wissen","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/de\/568126\/","title":{"rendered":"MS-Forschung: Kaum ein Patient landet noch im Rollstuhl | Leben &#038; Wissen"},"content":{"rendered":"<p>Multiple Sklerose gilt heute als behandelbar wie nie zuvor. Dank revolution\u00e4rer Medikamente wie Natalizumab und B-Zell-spezifischen Therapien bleiben 90 Prozent der Patienten auch zwei Jahrzehnte nach der Diagnose ohne Rollstuhl. <\/p>\n<p>Prof. Dr. Heinz Wiendl erkl\u00e4rt, wie moderne Therapien die Lebensqualit\u00e4t von MS-Betroffenen drastisch verbessert haben. Erfahren Sie mehr \u00fcber die Erfolgsgeschichte der Behandlung von Multipler Sklerose \u2013 jetzt mit BILDplus.<\/p>\n","protected":false},"excerpt":{"rendered":"Multiple Sklerose gilt heute als behandelbar wie nie zuvor. Dank revolution\u00e4rer Medikamente wie Natalizumab und B-Zell-spezifischen Therapien bleiben&hellip;\n","protected":false},"author":2,"featured_media":568127,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[137],"tags":[136957,29,30,141,232,638,18115,837,4608,45],"class_list":{"0":"post-568126","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-gesundheit","8":"tag-autoimmunkrankheiten","9":"tag-deutschland","10":"tag-germany","11":"tag-gesundheit","12":"tag-health","13":"tag-krankheiten","14":"tag-medikamente","15":"tag-medizin","16":"tag-multiple-sklerose","17":"tag-texttospeech"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/568126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/comments?post=568126"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/568126\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media\/568127"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media?parent=568126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/categories?post=568126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/tags?post=568126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}